Clinical trials: Dose Finding Study
Liver Carcinoma
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
The primary objective of the study is to select the dose of AVE1642 to be administered in patients with liver carcinoma not eligible for local treatment.
- Trial name
- NCT00791544
- Testing
- AVE1642, sorafenib, erlotinib
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Sanofi
Rhinoconjunctivitis, Allergies
Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy
The purpose of the study is to test whether vaccinations with CYT003-QbG10 can improve allergy symptoms in patients with house dust mite allergy. The active treatment will be compared against placebo.
- Trial name
- NCT00800332
- Testing
- CYT003-QbG10
- Where
- 8 sites in Estonia, Germany and 4 more
- Volunteers
- 300 people
- Sponsor
- Cytos Biotechnology AG
Advanced Solid Tumors
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult…
- Trial name
- ARTEMIDE-subQ (NCT07161414)
- Testing
- IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig
- Where
- 11 sites in United States, South Korea and 2 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus
Evaluate the efficacy, safety and tolerability of a 12-week treatment of 4 doses of ASP1941 compared to placebo in combination with metformin in adult patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on…
- Trial name
- BALANCE (NCT01117584)
- Testing
- ipragliflozin, Metformin
- Where
- 44 sites in United States, Hungary and 4 more
- Volunteers
- 343 people
- Sponsor
- Astellas Pharma Inc
Chronic Obstructive Pulmonary Disease
Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD
The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours.
- Trial name
- NCT00640484
- Testing
- carmoterol (CHF 4226), salmeterol
- Where
- 15 sites in United States
- Volunteers
- 57 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Hyperphosphatemia
Dose Finding Study to Treat High Phosphate Levels in the Blood.
Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period
- Trial name
- NCT02081534
- Testing
- AZD1722
- Where
- 41 sites in United States, Poland and 2 more
- Volunteers
- 162 people
- Sponsor
- Ardelyx
Multiple Sclerosis
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT01006265
- Testing
- ACT-128800 Dose 1, ACT-128800 Dose 2, ACT-128800 Dose 3
- Where
- 115 sites in United States, Australia and 21 more
- Volunteers
- 464 people
- Sponsor
- Actelion
HIV Infections
A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults
This is a phase 2b, randomized, multicenter, parallel group, partially blind (to GSK3640254 doses [100, 150 and 200 milligrams {mg}]), active controlled clinical trial.
- Trial name
- DOMINO (NCT04493216)
- Testing
- GSK3640254, ABC/3TC, FTC/TAF
- Where
- 65 sites in United States, Argentina and 9 more
- Volunteers
- 161 people
- Sponsor
- ViiV Healthcare
Malignant Glioma, Glioblastoma Multiforme
Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma
The purpose of this study is to evaluate the safety and biologically active dose of TM-601 in adult patients with recurrent malignant glioma.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma
- Trial name
- NCT00591058
- Testing
- TM-601
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- TransMolecular
Essential Hypertension
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of…
- Trial name
- NCT00758524
- Testing
- LCI699, Eplerenone
- Where
- United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with gemcitabine in patients with advanced solid tumors
- Trial name
- NCT00615446
- Testing
- SU011248; Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Pfizer
Focal Onset Seizure, Focal Onset Epilepsy
A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
This study will evaluate the safety, pharmacokinetics, and efficacy of three different doses of NBI-921352 versus placebo in adults with focal onset seizures
- Trial name
- NCT05159908
- Testing
- NBI-921352
- Where
- 28 sites in Australia, Belgium and 5 more
- Volunteers
- 101 people
- Sponsor
- Neurocrine Biosciences
Solid Tumor, Lymphoma
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in…
- Trial name
- NCT03013491
- Testing
- CX-072, ipilimumab, vemurafenib
- Where
- 31 sites in United States, Netherlands and 4 more
- Volunteers
- 196 people
- Sponsor
- CytomX Therapeutics
Allergic Rhinitis, Allergic Rhinoconjunctivitis
SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Birch based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Birch compared to placebo.
- Trial name
- NCT01639768
- Testing
- SUBLIVAC FIX Birch
- Where
- 20 sites in Czechia, Germany and 1 more
- Volunteers
- 270 people
- Sponsor
- HAL Allergy
Recurrent Prostate Cancer
Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study
When given to men with recurrent prostate cancer, the investigators hypothesize that POMx is effective in slowing the rise of PSA as measured by PSA doubling time in men following initial therapy for prostate cancer.
- Trial name
- NCT01220817
- Testing
- 3 POMx capsules, 1 POMx capsule
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- POM Wonderful LLC
Dyslipidemia
A Study in People With Abnormal Fat Levels in the Blood
The purposes of this study are to determine: The safety of the study medication and any side effects that might be associated with it; Whether the study medication can help patients with low levels of 'good' cholesterol (HDL-C)…
- Trial name
- NCT00116519
- Testing
- PPAR alpha
- Where
- 54 sites in United States
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Gut Microbiota, Gastrointestinal Symptoms
The Effects Of HMO On The Faecal Microbiota And On Gastrointestinal Symptoms In Healthy Volunteers
The study is a randomised, placebo-controlled, double-blind, parallel, dose-finding study with healthy volunteers. A total of 100 male and female volunteers will be included.
- Trial name
- HMO-VOL (NCT01927900)
- Testing
- HMO, Glucose
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Glycom A/S
Alpha Mannosidosis
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
This is a single-center, open-label, multiple-dose study of the efficacy and long-term safety of Lamazym for the treatment of patients with alpha-mannosidosis.
- Trial name
- NCT01285700
- Testing
- Lamazym
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Zymenex A/S
Pulmonary TB
Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB
This trial will assess the safety and efficacy of OPC-167832 combined with delamanid and bedaquiline in participants with drug-susceptible tuberculosis (DS-TB) administered for 17 weeks compared to rifampin, isoniazid…
- Trial name
- NCT05221502
- Testing
- Delamanid, Bedaquiline, RHEZ
- Where
- 6 sites in South Africa
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Hot Flushes
E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)
This dose-finding study is being conducted to select the daily oral dose of estetrol (E4) for the treatment of vasomotor symptoms (VMS) in post-menopausal women.
- Trial name
- NCT02834312
- Testing
- Estetrol
- Where
- Belgium
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Donesta Bioscience
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.